Companies · Biotechnology

Hydrocision Inc

NORTH BILLERICA · Biotechnology

Diligence memoA one-page analyst read on Hydrocision Inc — recommendation, valuation, rhythm, risks.
$9.2M
Total raised · real
4
Rounds
0.8×
Latest step-up
Top 47%
Sector rank · raised
Seed
Latest stage · inferred · Fri Nov 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Hydrocision Inc looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.70× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
  • Within the normal band (70% of peer median) for its niche.
Quiet
  • Last raise 19 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Hydrocision Inc is one of 4291 Biotechnology companies tracked from NORTH BILLERICA. By capital raised it ranks mid-pack (ahead of 54% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(b)
Reg D exemption
12
Investors (latest)
2024-11-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2008-11-18 Raised $3.0M (real) Modeled valuation $134M (est)$3.0M$134MSeed2008Seed · 2010-03-30 Raised $624K (real) Modeled valuation $28M (est)$624K$28MSeed2010Seed · 2017-03-09 Raised $3.0M (real) Modeled valuation $133M (est)$3.0M$133MSeed2017Seed · 2024-11-15 Raised $2.5M (real) Modeled valuation $10.0M (est)$2.5M$10.0MSeed2024+$624K+$3.0M+$2.5MCumulative $9.2M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M · 2008
Seed extension$624K · 2010
Seed extension$3.0M · 2017
Seed extension$2.5M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$10.0M
Base estimate est.
$1.8M
Conservative case
$23.9M
Upside case
$12.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $134.3M · 2008-11-182008Seed · modeled $27.7M · 2010-03-30Seed · modeled $133.2M · 2017-03-09Seed · modeled $10.0M · 2024-11-152024
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
1.6 yr
Elapsed time used
1.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
64 mo
Avg between rounds
$574K/yr
Capital velocity
17.6 yr
On record since
2008
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.3× above median
This company$9.2M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.5× above median
This company$2.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$10.0M
Sector median$64.2M

Raised more than 54% of sector peers (real $). Modeled value above 18% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #126 of 207.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Mesentech Inc. · Seed Raised $3.9M · modeled $65.6M (est)Marlinspike Therapeutics, Inc. · Seed Raised $3.5M · modeled $64.3M (est)Microbial Machines, Inc. · Seed Raised $3.9M · modeled $63.6M (est)Pearl Diagnostics, Inc. · Seed Raised $3.5M · modeled $62.8M (est)Crossfire Medical Inc · Seed Raised $3.0M · modeled $57.5M (est)Design Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $56.9M (est)Tekv Holdings LLC · Seed Raised $4.0M · modeled $55.4M (est)Mi-Helper, Inc. · Seed Raised $4.0M · modeled $50.9M (est)Thelium Therapeutics Inc. · Seed Raised $3.1M · modeled $50.7M (est)Turtle Health, Inc. · Seed Raised $2.7M · modeled $49.1M (est)Accufix Holdings, Inc. · Seed Raised $4.2M · modeled $46.7M (est)Kyttaro Ltd · Seed Raised $5.2M · modeled $45.5M (est)Hydrocision Inc (this company) Raised $9.2M · modeled $10.0M (est)Hydrocision Inc
CompanyStageRaised · realValue · estvs peer med.
Mesentech Inc.Seed$3.9M$65.6M4.61×
Marlinspike Therapeutics, Inc.Seed$3.5M$64.3M4.52×
Microbial Machines, Inc.Seed$3.9M$63.6M4.47×
Pearl Diagnostics, Inc.Seed$3.5M$62.8M4.41×
Crossfire Medical IncSeed$3.0M$57.5M4.04×
Design Pharmaceuticals, Inc.Seed$3.0M$56.9M4.00×
Tekv Holdings LLCSeed$4.0M$55.4M3.89×
Mi-Helper, Inc.Seed$4.0M$50.9M3.58×
Thelium Therapeutics Inc.Seed$3.1M$50.7M3.56×
Turtle Health, Inc.Seed$2.7M$49.1M3.45×
Accufix Holdings, Inc.Seed$4.2M$46.7M3.28×
Kyttaro LtdSeed$5.2M$45.5M3.20×
Hydrocision Inc this companySeed$9.2M$10.0M0.70×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.0M2008-11-18$15.1M$134.3M85%
Seed$624K2010-03-30$3.1M$27.7M85%
Seed$3.0M2017-03-09$15.0M$133.2M90%
Seed$2.5M2024-11-15$12.7M$10.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.0M2008-11-18
    • First recorded raise — entered as Seed.
    • 11 investors on this round.
  2. Seed$624K2010-03-30
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 4.8× smaller than the prior — bridge or down round.
    • 8 investors on this round.
  3. Seed$3.0M2017-03-09
    • Raised again after 83 mo — slower than the ~14 mo sector norm.
    • Round 4.8× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 10 investors on this round.
  4. Seed$2.5M2024-11-15
    • Raised again after 92 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 12 investors on this round.
Intelligence
2030 ~Q1
Modeled next raise · ~64mo cadence
$2.5M
Modeled next size est.range $2.5M$4.0M
0.8×
Last step-up
$574K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Marc Goldberg8 other2008-11
Dennis Costello5 other2008-11
Doug Wall3 other2017-03
MARC E. GOLDBERG3 other2024-11
Jeffrey T Barnes2 other2008-11
John C Miller2 other2008-11
Terry Wall2 other2017-03
Thomas D. Abert2 other2024-11
HOWARD DONNELLY1 other2017-03
Richard J Lim1 other2008-11
Alastair J.T. Clemow, Ph.D.2008-11
Alastair JT Clemow PhD2010-03
BRYAN E. GRULKE2024-11
DOUG E. WALL2024-11
Douglas J Daniels2008-11
HOWARD W. DONNELLY2024-11
James H Hill2008-11
Jonathan JT Fleming2010-03
Kevin P Staid2008-11
Lew Bennett2008-11
LONG E. ZHAN2024-11
Marc JT Goldberg2010-03
Patricia A Van Blarcom2008-11
PATRICIA VANBLARCOM2017-03
Registry & provenance

Hydrocision Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1031309
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cambridge Endoscopic Devices IncBiotechnologySeed$12.0M$129.8Mnetwork1 shared operator · same sector · same stage
Verax Biomedical IncBiotechnologySeries A$45.8M$91.8Mnetwork2 shared operators · same sector
ZS Genetics IncBiotechnologySeed$2.9M$7.5Mnetwork1 shared operator · same sector · same stage
CohBar, Inc.BiotechnologySeries A$8.7M$77.5Mnetwork1 shared operator · same sector
Claros Diagnostics IncOtherSeed$4.0M$74.4Mnetwork2 shared operators · same stage
Pacific Diabetes Technologies, Inc.BiotechnologySeed$9.0M$8.1Msame sector · same stage
ProPhase Labs, Inc.BiotechnologySeed$8.4M$8.1Msame sector · same stage
Roxwood Medical, Inc.OtherSeries A$10.4M$97.8Mnetwork2 shared operators
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
PathCision Medicine, Inc.BiotechnologySeed$20.4M85%
CapsoVision, IncBiotechnologySeries C$40.1M83%
Waterdiam Group, LLCBiotechnologySeries A$302.5M83%
Aquaro Histology, Inc.BiotechnologySeries A$354.7M82%
Aqua Medical LlcBiotechnologyPre-Seed$11.3M81%
Liquet Medical Inc.BiotechnologySeed$3.9M81%
Liminal BioSciences Inc.BiotechnologySeries B$1.0B80%
Excision BioTherapeutics IncBiotechnologySeries C$338.1M80%
Frequently asked
How much funding has Hydrocision Inc raised?
Hydrocision Inc has raised approximately $9.2M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Hydrocision Inc's estimated valuation?
Provath's modeled valuation for Hydrocision Inc is approximately $10.0M (modeled range $1.8M–$23.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Hydrocision Inc at?
Hydrocision Inc's latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Nov 15.
What does Hydrocision Inc do and where is it based?
Hydrocision Inc operates in the Biotechnology sector, based in NORTH BILLERICA.
Explore related

See where Hydrocision Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Hydrocision Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.